Alkermes plc $ALKS Shares Bought by Diversified Trust Co

Diversified Trust Co lifted its stake in Alkermes plc (NASDAQ:ALKS) by 0.8% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 44,232 shares of the company’s stock after purchasing an additional 372 shares during the quarter. Diversified Trust Co’s holdings in Alkermes were worth $1,265,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of ALKS. Twin Tree Management LP acquired a new stake in Alkermes during the 1st quarter worth $29,000. Brooklyn Investment Group boosted its position in shares of Alkermes by 1,071.1% in the first quarter. Brooklyn Investment Group now owns 1,054 shares of the company’s stock worth $35,000 after acquiring an additional 964 shares during the last quarter. Quantbot Technologies LP boosted its position in shares of Alkermes by 54.5% in the first quarter. Quantbot Technologies LP now owns 1,091 shares of the company’s stock worth $36,000 after acquiring an additional 385 shares during the last quarter. USA Financial Formulas acquired a new position in Alkermes during the first quarter valued at approximately $49,000. Finally, Fifth Third Bancorp lifted its position in shares of Alkermes by 54.4% during the first quarter. Fifth Third Bancorp now owns 1,479 shares of the company’s stock worth $49,000 after purchasing an additional 521 shares in the last quarter. 95.21% of the stock is owned by hedge funds and other institutional investors.

Alkermes Stock Performance

Shares of NASDAQ:ALKS opened at $27.79 on Monday. Alkermes plc has a 52-week low of $25.17 and a 52-week high of $36.45. The business’s 50 day simple moving average is $28.00 and its two-hundred day simple moving average is $29.59. The firm has a market cap of $4.59 billion, a P/E ratio of 13.36, a PEG ratio of 1.56 and a beta of 0.53.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.10. The business had revenue of $390.66 million for the quarter, compared to analyst estimates of $343.20 million. Alkermes had a return on equity of 24.86% and a net margin of 23.15%.Alkermes’s quarterly revenue was down 2.1% compared to the same quarter last year. During the same period last year, the company posted $1.16 earnings per share. Alkermes has set its FY 2025 guidance at 1.030-1.210 EPS. On average, equities analysts forecast that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ALKS. Wells Fargo & Company upgraded shares of Alkermes to a “strong-buy” rating in a research note on Wednesday, September 3rd. Needham & Company LLC set a $43.00 price target on shares of Alkermes in a report on Tuesday, September 9th. HC Wainwright restated a “neutral” rating and set a $46.00 price objective on shares of Alkermes in a report on Tuesday, September 9th. The Goldman Sachs Group began coverage on Alkermes in a report on Tuesday, July 15th. They issued a “buy” rating and a $43.00 price objective on the stock. Finally, Royal Bank Of Canada increased their price target on Alkermes from $40.00 to $42.00 and gave the company a “sector perform” rating in a report on Wednesday, July 30th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Alkermes has a consensus rating of “Moderate Buy” and a consensus target price of $41.85.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.